Persistent unmet need
Patients may experience angina or ischemia despite the absence of obstructive disease in the major coronary arteries.
Coronary microvascular dysfunction
Identifying and targeting distinct mechanisms ofcoronary microvascular dysfunction.
Lucier Pharmaceuticals is a preclinical-stage biopharmaceutical company developing injectable and oral small-molecule programs for the mechanism-based assessment and treatment of coronary microvascular dysfunction.
Scientific focus
Coronary arteriolar biologyOur therapeutic focus
A complex condition with limited mechanism-based treatment options
Patients with coronary microvascular dysfunction may experience angina or ischemia despite the absence of obstructive coronary disease. Because CMD can arise from distinct functional and structural mechanisms, a single diagnostic or treatment approach may not be appropriate for every patient.
Biologically heterogeneous
CMD can arise from distinct functional and structural mechanisms within the coronary microcirculation.
Advance targeted programs
Lucier is developing programs intended to assess and address defined pathways involved in abnormal coronary arteriolar regulation.
Scientific strategy
Focused on coronary arteriolar biology.
Coronary arterioles regulate vascular resistance and tissue-level blood flow. Dysfunction at this level can impair myocardial perfusion even without obstructive disease in the major coronary arteries. Lucier's research into abnormal coronary arteriolar regulation informs the development of its small-molecule programs for coronary microvascular dysfunction.
Explore the pipelineCoronary circulationConceptual view
- Epicardial arteryConducts blood
- Small arteryDistributes flow
- ArterioleHelps regulate resistance
- Capillary networkSupports tissue exchange
Simplified conceptual diagram for scientific context. Vessel sizes and relationships are not drawn to scale.
Our pipeline
Development pipeline
Lucier is advancing complementary injectable and oral candidates within its lead ROCK inhibitor program for coronary microvascular dysfunction.
ROCK inhibitor program
LU-1001
Injectable assessment candidate
Current development status: Preclinical development
LU-1002
Oral therapeutic candidate
Current development status: Preclinical development
Our company
Built on coronary arteriolar biology. Guided by drug development experience.
Lucier's programs are informed by scientific findings originating at Texas A&M University and supported by advisors spanning vascular biology, translational research, preclinical development, and biotechnology strategy.
LeadershipGuangrong Lu, MD, MBA
Founder, President and CEO
Co-inventorView external profile
AdvisorLih Kuo, PhD
Scientific Advisor
Co-inventor · Regents ProfessorView external profile
AdvisorE.L. Berryman
Preclinical Development Advisor
Registered ToxicologistView external profile
AdvisorLee Schalop, MD
Business Advisor
Investor and EntrepreneurView external profileNews and publications
Scientific evidence and company progress.
Follow Lucier's peer-reviewed publications, scientific presentations, and company updates.
View News and PublicationsLucier research on ROCK2-mediated coronary arteriolar constriction presented at AHA 2025
Read abstract 4335925 in Circulation.
Connect with Lucier
Partnering to advance microvascular therapeutics.
Lucier welcomes discussions regarding pharmaceutical partnerships, investment, translational studies, clinical collaboration, and drug development.
Contact Lucier Please do not send personal health information.